U.S., Aug. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07768358) titled 'Tucatinib Continuation Study' on Aug. 12.
Brief Summary: The purpose of this protocol is to give continued access to tucatinib eligible participants. It also enables ongoing safety follow-up for those who continue to benefit from the study treatment. These participants were part of Pfizer-sponsored tucatinib parent studies that will be closed. Additional follow-up safety information will be collected. This will allow further understanding of the safety profile of tucatinib in participants who continue to receive the study treatment.
Study Start Date: Aug. 24
Study Type: INTERVENTIONAL
Condition:
HER2-positive Breast Cancer
Cervi...